SciTech Development is a clinical-stage specialty pharmaceutical company focused on advancing cancer treatment through innovative drug delivery technologies. The company has developed a proprietary nanoparticle delivery platform known as the SciTech Drug Delivery Platform (SDP), which enhances the bioavailability of water-insoluble therapeutics while improving safety profiles. Their lead drug candidate, ST-001 nanoFenretinide, combines this delivery platform with fenretinide, a synthetic retinoid derivative that has shown promise as an anticancer agent. The ST-001 formulation is designed for rapid intravenous delivery of high doses of fenretinide, addressing the challenges of low bioavailability that have historically limited the drug's clinical use.

The SDP utilizes a biomimetic phospholipid matrix that not only facilitates the effective delivery of fenretinide but also has the potential to deliver other therapeutics, including non-cancer drugs. This platform aims to optimize therapeutic efficacy while minimizing toxicity, particularly avoiding the triglyceride toxicity associated with traditional formulations. SciTech's approach is supported by extensive clinical data demonstrating fenretinide's safety and efficacy, and the company is actively seeking funding and partnerships to advance clinical trials for ST-001, which targets underserved cancer indications such as T-cell lymphoma and small cell lung cancer.

United States

SciTech Development is a Specialty Pharmaceutical Company dedicated to advancing cancer treatment through safer drug delivery. They are based in Michigan, USA and are known for their innovative drug delivery platform SDP that engineers new therapeutics for better & broader clinical applications.

SciTech Development

Company Details